Graeme Bell
Chief Executive Officer at Valo Health, Inc.
Profile
Graeme Bell is currently the CEO, Chief Financial & People Officer at Valo Health, Inc. and Valo Health LLC.
He is also the Director at Cytoimmune Therapeutics, Inc. Previously, he worked as the Director-Investor Relations at Merck & Co., Inc. from 2007 to 2009.
He also served as the Director-Claims Development at Direct Group Ltd.
Additionally, he was the Chief Financial Officer & Executive Vice President at Anacor Pharmaceuticals LLC from 2015 to 2016.
From 2016 to 2018, he held the position of CFO, Principal Accounting Officer & Executive VP at Intellia Therapeutics, Inc. He then became the Chief Financial Officer at Tmunity Therapeutics, Inc. from 2018 to 2020.
Mr. Bell obtained an MBA from the University of Durham.
Currently, he is the CEO, Chief Financial & People Officer at Valo Health, Inc. and Valo Health LLC, and the Director at Cytoimmune Therapeutics, Inc.
Graeme Bell active positions
| Companies | Position | Start |
|---|---|---|
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Director/Board Member | 2023-02-28 |
Valo Health LLC
 Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | Chief Executive Officer | 2024-01-15 |
Valo Health, Inc.
 Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The private company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | Chief Executive Officer | 2024-01-14 |
Former positions of Graeme Bell
| Companies | Position | End |
|---|---|---|
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Director of Finance/CFO | 2020-05-31 |
| INTELLIA THERAPEUTICS, INC. | Director of Finance/CFO | 2018-08-02 |
| ANACOR PHARMACEUTICALS INC | Director of Finance/CFO | 2016-10-31 |
| MERCK & CO., INC. | Public Communications Contact | 2009-11-03 |
Direct Group Ltd.
 Direct Group Ltd. Insurance Brokers/ServicesFinance Direct Group Ltd. provides insurance services. Its products include property, motor, casualty, and life insurance. The company was founded in 1990 and is headquartered in Doncaster, the United Kingdom. | Corporate Officer/Principal | - |
Training of Graeme Bell
| University of Durham | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The private company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | Finance |
Direct Group Ltd.
Direct Group Ltd. Insurance Brokers/ServicesFinance Direct Group Ltd. provides insurance services. Its products include property, motor, casualty, and life insurance. The company was founded in 1990 and is headquartered in Doncaster, the United Kingdom. | Finance |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Commercial Services |
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | Technology Services |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Health Technology |
- Stock Market
- Insiders
- Graeme Bell
